Equities Analysts Set Expectations for BTAI Q3 Earnings

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – HC Wainwright dropped their Q3 2024 earnings per share (EPS) estimates for shares of BioXcel Therapeutics in a research report issued to clients and investors on Monday, October 21st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.55) per share for the quarter, down from their previous forecast of ($0.44). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($2.03) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.54) EPS.

A number of other analysts have also issued reports on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $7.00 target price on shares of BioXcel Therapeutics in a research report on Friday, August 30th. UBS Group dropped their price target on shares of BioXcel Therapeutics from $3.50 to $1.00 and set a “neutral” rating on the stock in a research note on Friday, August 9th.

BioXcel Therapeutics Price Performance

Shares of BTAI opened at $0.58 on Wednesday. The stock has a market cap of $21.75 million, a PE ratio of -0.11 and a beta of 0.28. BioXcel Therapeutics has a 12 month low of $0.51 and a 12 month high of $5.62. The stock’s 50-day moving average is $0.60 and its two-hundred day moving average is $1.31.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its earnings results on Tuesday, August 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.55. The business had revenue of $1.10 million for the quarter, compared to analyst estimates of $0.80 million. During the same quarter in the previous year, the firm posted ($1.83) EPS.

Hedge Funds Weigh In On BioXcel Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Armistice Capital LLC boosted its stake in BioXcel Therapeutics by 705.2% during the 2nd quarter. Armistice Capital LLC now owns 2,987,000 shares of the company’s stock valued at $3,823,000 after acquiring an additional 2,616,027 shares during the last quarter. Rosalind Advisors Inc. acquired a new stake in BioXcel Therapeutics during the second quarter valued at approximately $51,000. Point72 Asia Singapore Pte. Ltd. bought a new position in BioXcel Therapeutics during the 2nd quarter worth approximately $39,000. XTX Topco Ltd grew its position in shares of BioXcel Therapeutics by 49.0% in the 2nd quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock worth $60,000 after acquiring an additional 15,291 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of BioXcel Therapeutics by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,099,375 shares of the company’s stock valued at $3,100,000 after acquiring an additional 9,912 shares during the last quarter. 30.68% of the stock is currently owned by hedge funds and other institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.